Broadfin Capital Lowered By $7.68 Million Its Aerie Pharmaceuticals (Call) (AERI) Stake; Inphi (IPHI)’s Sentiment Is 0.85

February 21, 2018 - By Linda Rogers

Broadfin Capital Llc decreased Aerie Pharmaceuticals Inc (Call) (AERI) stake by 51.61% reported in 2017Q3 SEC filing. Broadfin Capital Llc sold 160,000 shares as Aerie Pharmaceuticals Inc (Call) (AERI)’s stock declined 8.47%. The Broadfin Capital Llc holds 150,000 shares with $7.29 million value, down from 310,000 last quarter. Aerie Pharmaceuticals Inc (Call) now has $2.08 billion valuation. The stock decreased 2.21% or $1.2 during the last trading session, reaching $53. About 192,425 shares traded. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has risen 180.20% since February 21, 2017 and is uptrending. It has outperformed by 163.50% the S&P500.

Inphi Corporation provides high-speed analog and mixed signal semiconductor solutions for the communications, datacenter, and computing markets worldwide. The company has market cap of $1.08 billion. The companyÂ’s analog and mixed signal semiconductor solutions offers high signal integrity at data speeds while reducing system power consumption. It currently has negative earnings. The Company’s semiconductor solutions are designed to address bandwidth bottlenecks in networks, maximize throughput and minimize latency in computing environments, and enable the rollout of next generation communications and datacenter infrastructures.

Since January 1, 0001, it had 0 insider buys, and 4 insider sales for $2.76 million activity.

S Squared Technology Llc holds 5.15% of its portfolio in Inphi Corporation for 153,576 shares. Herald Investment Management Ltd owns 162,000 shares or 2.08% of their US portfolio. Moreover, Quentec Asset Management Llc has 1.78% invested in the company for 448,216 shares. The Us-based Grandeur Peak Global Advisors Llc has invested 1.55% in the stock. Ranger Investment Management L.P., a Texas-based fund reported 505,575 shares.

The stock increased 0.28% or $0.07 during the last trading session, reaching $25.27. About 1.13M shares traded or 21.75% up from the average. Inphi Corporation (IPHI) has risen 38.34% since February 21, 2017 and is uptrending. It has outperformed by 21.64% the S&P500.

Analysts await Inphi Corporation (NYSE:IPHI) to report earnings on May, 1. They expect $-0.34 earnings per share, down 247.83% or $0.57 from last year’s $0.23 per share. After $0.09 actual earnings per share reported by Inphi Corporation for the previous quarter, Wall Street now forecasts -477.78% negative EPS growth.

Ratings analysis reveals 60% of Inphi’s analysts are positive. Out of 5 Wall Street analysts rating Inphi, 3 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $39.0 while the high is $55.0. The stock’s average target of $48 is 89.95% above today’s ($25.27) share price. IPHI was included in 5 notes of analysts from August 30, 2016. The rating was initiated by JP Morgan with “Overweight” on Tuesday, August 30. Cowen & Co initiated it with “Market Perform” rating and $39.0 target in Friday, October 14 report. The stock of Inphi Corporation (NYSE:IPHI) has “Market Perform” rating given on Wednesday, September 7 by Northland Capital. Stifel Nicolaus maintained Inphi Corporation (NYSE:IPHI) rating on Thursday, October 13. Stifel Nicolaus has “Buy” rating and $48.0 target. Needham maintained Inphi Corporation (NYSE:IPHI) on Wednesday, November 2 with “Strong Buy” rating.

Investors sentiment increased to 1.73 in 2017 Q3. Its up 0.56, from 1.17 in 2017Q2. It increased, as 14 investors sold AERI shares while 41 reduced holdings. 26 funds opened positions while 69 raised stakes. 34.42 million shares or 8.89% more from 31.61 million shares in 2017Q2 were reported. Schwab Charles Investment Mgmt invested in 152,668 shares or 0.01% of the stock. Price T Rowe Assocs Inc Md reported 273,373 shares stake. Cranbrook Wealth Mgmt Lc invested 0.01% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Rhenman Prtn Asset Mgmt Ab reported 120,932 shares stake. Foresite Cap Management Ii Limited holds 32.95% or 1.67M shares. 71,210 were reported by Hudson Bay Mgmt Limited Partnership. Harvey Inc accumulated 0.49% or 24,800 shares. California Public Employees Retirement Sys invested in 7,525 shares. Invesco reported 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Ameriprise reported 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Bailard has invested 0.06% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Susquehanna Grp Limited Liability Partnership stated it has 56,600 shares. Partner Investment Mgmt LP has 1.46% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 31,702 shares. 15,900 were reported by Dekabank Deutsche Girozentrale. Teachers Retirement Sys Of The State Of Kentucky stated it has 0.04% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Among 15 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 15 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aerie Pharmaceuticals had 47 analyst reports since August 7, 2015 according to SRatingsIntel. The stock has “Buy” rating by H.C. Wainwright on Friday, February 16. The company was maintained on Thursday, September 15 by RBC Capital Markets. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by Cowen & Co on Tuesday, September 26. The stock has “Buy” rating by Stifel Nicolaus on Thursday, September 17. Cowen & Co maintained it with “Buy” rating and $10000 target in Wednesday, August 2 report. The company was maintained on Thursday, July 27 by Stifel Nicolaus. Canaccord Genuity maintained the shares of AERI in report on Wednesday, August 16 with “Buy” rating. On Thursday, September 15 the stock rating was maintained by Needham with “Buy”. The firm has “Buy” rating by Cantor Fitzgerald given on Monday, December 18. H.C. Wainwright maintained it with “Buy” rating and $6900 target in Wednesday, August 2 report.

Analysts await Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) to report earnings on March, 6. They expect $-1.47 earnings per share, down 68.97% or $0.60 from last year’s $-0.87 per share. After $-0.89 actual earnings per share reported by Aerie Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 65.17% negative EPS growth.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>